TEMPO-HCC represents a paradigm shift from static binary classification toward clinically actionable temporal risk prediction, and provides an auditable evidence chain linking macro-scale radiologic phenotypes to micro-scale histopathologic patterns.
Abstract
Hepatocellular carcinoma (HCC) exhibits substantial interpatient heterogeneity, leading to markedly variable outcomes and survival even among patients with similar stages and imaging phenotypes. Mainstream staging systems remain suboptimal, whereas pathology-dependent factors and high-cost genomic assays are neither scalable nor timely for clinical decision-making. Existing algorithms provide coarse risk stratification or static binary predictions, failing to capture the time-varying risk of death. We developed and externally validated TEMPO-HCC, a multimodal deep survival model with hierarchical interpretability, to estimate individualized overall survival risk trajectories after curative-intent resection. We curated a six-center cohort of 1475 patients and integrated multiphasic MRI, postoperative H&E whole-slide images, and perioperative predictors. A discrete-time survival head generated probabilities at 1, 2, 3, and 5 years after surgery. TEMPO-HCC outperformed unimodal models and guideline-based staging systems, achieving C-index of 0.751 and time-dependent AUCs of 0.836, 0.781, 0.812, and 0.680 at 12, 24, 36, and 60 months, respectively, in the external validation cohort. TEMPO-HCC represents a paradigm shift from static binary classification toward clinically actionable temporal risk prediction. Its hierarchical interpretability provides an auditable evidence chain linking macro-scale radiologic phenotypes to micro-scale histopathologic patterns. Importantly, augmenting guideline staging with TEMPO-HCC improved discrimination, enabling personalized postoperative surveillance and risk-adapted clinical management.
Background Surgical resection is the standard treatment for stage I lung adenocarcinoma, in most cases without additional systemic adjuvant treatment. A substantial proportion of stage I cases recur, with a 5-year survival rate <50%. Clinical data suggest that adjuvant treatment, including immune checkpoint inhibitor t...
O. Kilim, O. Pipek, Z. Sztupinszki et al.· Immuno-Oncology Technology· 0 citations
Accurately predicting the risk of early liver metastases (ELM) and identifying patients who are most likely to benefit from neoadjuvant therapy (NAT) are critical for pancreatic ductal adenocarcinoma (PDAC). Here, we develop a Mamba-based predictive model that integrates imaging features from both the primary pancreati...
Ben Zhao, Zhi-Fang Gong, W. Xiao et al.· Nature Communications· 0 citations
The deep learning-based multi-cancer disease-free survival model performed robustly across cancer subtypes, with the nomogram improving risk stratification, particularly for stage I malignancies, complementing existing staging.
Si-Teng Chen, En-Cheng Zhang, Fu-Kang Sun et al.· Cancers· 0 citations
Purpose To develop HepaKineticNet, a deep learning framework that models inter-phase kinetic dynamics on multi-phase contrast-enhanced CT (CECT) to generate intratumoral heterogeneity (ITH) maps, and to assess in an independent external cohort whether a clinical–radiomics fusion model improves overall survival (OS) pre...
Jin-Peng Li, Wen-Zhe Bu, Xiaotian Hanming et al.· Journal of Hepatocellular Ca...· 0 citations
The findings underscore the potential of the proposed multimodal deep learning framework to provide accessible, accurate, and generalizable recurrence risk prediction using routinely available clinical data, potentially supporting more informed treatment decisions and personalized post-treatment monitoring in real-worl...
R. Chang, Hsiang-Wei Huang, Szu-Yen Kuo et al.· Journal of imaging informati...· 0 citations
A multi-tier, explainable AI framework designed to risk-stratify patients and predict overall survival using clinical and genomic covariates is developed and demonstrates that explainable machine learning models can robustly predict survivability and highlight actionable features for oncology dashboards.
P. Nalela· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.